Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 529 to 539 of 539 entries
Sorted by: Best Match Show Resources per page
Identifying an elusive target with the help of an unproven technique.

Molecular psychiatry

Weiser M, Davidson M.
PMID: 34244619
Mol Psychiatry. 2021 Jul 09; doi: 10.1038/s41380-021-01213-y. Epub 2021 Jul 09.

No abstract available.

Cite
Weiser M, Davidson M. Identifying an elusive target with the help of an unproven technique. Mol Psychiatry. 2021;doi: 10.1038/s41380-021-01213-y.
Weiser, M., & Davidson, M. (2021). Identifying an elusive target with the help of an unproven technique. Molecular psychiatry, . https://doi.org/10.1038/s41380-021-01213-y
Weiser, Mark, and Davidson, Michael. "Identifying an elusive target with the help of an unproven technique." Molecular psychiatry vol. (2021). doi: https://doi.org/10.1038/s41380-021-01213-y
Weiser M, Davidson M. Identifying an elusive target with the help of an unproven technique. Mol Psychiatry. 2021 Jul 09; doi: 10.1038/s41380-021-01213-y. Epub 2021 Jul 09. PMID: 34244619.
Copy Download .nbib Format: NLM
Preventing opioid use disorder and misuse in asymptomatic primary care patients: A call for relevant primary prevention intervention research.

Preventive medicine

Davidson KW, Mangione CM, Krist AH, Curry SJ.
PMID: 34861337
Prev Med. 2021 Nov 30;106898. doi: 10.1016/j.ypmed.2021.106898. Epub 2021 Nov 30.

To contribute to the national effort to combat the opioid crisis, the United States Preventive Services Task Force (USPSTF) commissioned a scoping review to describe the state of evidence for the primary prevention of opioid misuse or use disorder...

Cite
Davidson KW, Mangione CM, Krist AH, et al. Preventing opioid use disorder and misuse in asymptomatic primary care patients: A call for relevant primary prevention intervention research. Prev Med. 2021;106898doi: 10.1016/j.ypmed.2021.106898.
Davidson, K. W., Mangione, C. M., Krist, A. H., & Curry, S. J. (2021). Preventing opioid use disorder and misuse in asymptomatic primary care patients: A call for relevant primary prevention intervention research. Preventive medicine, 106898. https://doi.org/10.1016/j.ypmed.2021.106898
Davidson, Karina W, et al. "Preventing opioid use disorder and misuse in asymptomatic primary care patients: A call for relevant primary prevention intervention research." Preventive medicine vol. (2021): 106898. doi: https://doi.org/10.1016/j.ypmed.2021.106898
Davidson KW, Mangione CM, Krist AH, Curry SJ. Preventing opioid use disorder and misuse in asymptomatic primary care patients: A call for relevant primary prevention intervention research. Prev Med. 2021 Nov 30;106898. doi: 10.1016/j.ypmed.2021.106898. Epub 2021 Nov 30. PMID: 34861337.
Copy Download .nbib Format: NLM
Considerations for using population frequency data in germline variant interpretation: Cancer syndrome genes as a model.

Human mutation

Davidson AL, Leonard C, Koufariotis LT, Parsons MT, Hollway GE, Pearson JV, Newell F, Waddell N, Spurdle AB.
PMID: 33600021
Hum Mutat. 2021 May;42(5):530-536. doi: 10.1002/humu.24183. Epub 2021 Mar 01.

Aggregate population genomics data from large cohorts are vital for assessing germline variant pathogenicity. However, there are no specifications on how sequencing quality metrics should be considered, and whether exome-derived and genome-derived allele frequencies should be considered in isolation....

Cite
Davidson AL, Leonard C, Koufariotis LT, et al. Considerations for using population frequency data in germline variant interpretation: Cancer syndrome genes as a model. Hum Mutat. 2021;42(5):530-536doi: 10.1002/humu.24183.
Davidson, A. L., Leonard, C., Koufariotis, L. T., Parsons, M. T., Hollway, G. E., Pearson, J. V., Newell, F., Waddell, N., & Spurdle, A. B. (2021). Considerations for using population frequency data in germline variant interpretation: Cancer syndrome genes as a model. Human mutation, 42(5), 530-536. https://doi.org/10.1002/humu.24183
Davidson, Aimee L, et al. "Considerations for using population frequency data in germline variant interpretation: Cancer syndrome genes as a model." Human mutation vol. 42,5 (2021): 530-536. doi: https://doi.org/10.1002/humu.24183
Davidson AL, Leonard C, Koufariotis LT, Parsons MT, Hollway GE, Pearson JV, Newell F, Waddell N, Spurdle AB. Considerations for using population frequency data in germline variant interpretation: Cancer syndrome genes as a model. Hum Mutat. 2021 May;42(5):530-536. doi: 10.1002/humu.24183. Epub 2021 Mar 01. PMID: 33600021.
Copy Download .nbib Format: NLM
Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications.

Frontiers in medicine

Hindocha S, Campbell D, Ahmed M, Giorgakoudi K, Sharma B, Yousaf N, Molyneaux P, Hunter B, Kalsi H, Cui W, Davidson M, Bhosle J, Minchom A, Locke I, McDonald F, O'Brien M, Popat S, Lee RW.
PMID: 34790682
Front Med (Lausanne). 2021 Nov 01;8:764563. doi: 10.3389/fmed.2021.764563. eCollection 2021.

Pneumonitis is a well-described, potentially life-threatening adverse effect of immune checkpoint inhibitors (ICI) and thoracic radiotherapy. It can require additional investigations, treatment, and interruption of cancer therapy. It is important for clinicians to have an awareness of its incidence...

Cite
Hindocha S, Campbell D, Ahmed M, et al. Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications. Front Med (Lausanne). 2021;8:764563doi: 10.3389/fmed.2021.764563.
Hindocha, S., Campbell, D., Ahmed, M., Giorgakoudi, K., Sharma, B., Yousaf, N., Molyneaux, P., Hunter, B., Kalsi, H., Cui, W., Davidson, M., Bhosle, J., Minchom, A., Locke, I., McDonald, F., O'Brien, M., Popat, S., & Lee, R. W. (2021). Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications. Frontiers in medicine, 8764563. https://doi.org/10.3389/fmed.2021.764563
Hindocha, Sumeet, et al. "Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications." Frontiers in medicine vol. 8 (2021): 764563. doi: https://doi.org/10.3389/fmed.2021.764563
Hindocha S, Campbell D, Ahmed M, Giorgakoudi K, Sharma B, Yousaf N, Molyneaux P, Hunter B, Kalsi H, Cui W, Davidson M, Bhosle J, Minchom A, Locke I, McDonald F, O'Brien M, Popat S, Lee RW. Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications. Front Med (Lausanne). 2021 Nov 01;8:764563. doi: 10.3389/fmed.2021.764563. eCollection 2021. PMID: 34790682; PMCID: PMC8591134.
Copy Download .nbib Format: NLM
Differences in the Prevalence of Screen-Detected Depression After Acute Coronary Syndrome Between Health Systems in the USA: Findings from CODIACS-QoL Randomized Controlled Trial.

Journal of general internal medicine

Moise N, Davidson KW, Clarke GN, Dolor RJ, Margolis KL, Kronish IM.
PMID: 34355350
J Gen Intern Med. 2021 Aug 05; doi: 10.1007/s11606-021-07049-0. Epub 2021 Aug 05.

No abstract available.

Cite
Moise N, Davidson KW, Clarke GN, et al. Differences in the Prevalence of Screen-Detected Depression After Acute Coronary Syndrome Between Health Systems in the USA: Findings from CODIACS-QoL Randomized Controlled Trial. J Gen Intern Med. 2021;doi: 10.1007/s11606-021-07049-0.
Moise, N., Davidson, K. W., Clarke, G. N., Dolor, R. J., Margolis, K. L., & Kronish, I. M. (2021). Differences in the Prevalence of Screen-Detected Depression After Acute Coronary Syndrome Between Health Systems in the USA: Findings from CODIACS-QoL Randomized Controlled Trial. Journal of general internal medicine, . https://doi.org/10.1007/s11606-021-07049-0
Moise, Nathalie, et al. "Differences in the Prevalence of Screen-Detected Depression After Acute Coronary Syndrome Between Health Systems in the USA: Findings from CODIACS-QoL Randomized Controlled Trial." Journal of general internal medicine vol. (2021). doi: https://doi.org/10.1007/s11606-021-07049-0
Moise N, Davidson KW, Clarke GN, Dolor RJ, Margolis KL, Kronish IM. Differences in the Prevalence of Screen-Detected Depression After Acute Coronary Syndrome Between Health Systems in the USA: Findings from CODIACS-QoL Randomized Controlled Trial. J Gen Intern Med. 2021 Aug 05; doi: 10.1007/s11606-021-07049-0. Epub 2021 Aug 05. PMID: 34355350.
Copy Download .nbib Format: NLM
Mannosylation of pH-sensitive liposomes promoted cytoplasmic delivery of protein to macrophages: green fluorescent protein (GFP) performed as an endosomal escape tracer.

Pharmaceutical development and technology

Yang K, Tang M, Chang HH, Kanamala M, Davidson AJ, Wu Z.
PMID: 34396913
Pharm Dev Technol. 2021 Nov;26(9):1000-1009. doi: 10.1080/10837450.2021.1969406. Epub 2021 Aug 26.

Conventional non-pH-sensitive liposomes for cytoplasmic delivery of protein suffer from poor efficiency. Here we investigated mannosylated pH-sensitive liposomes (MAN-PSL) for cytoplasmic delivery of protein to macrophages RAW 264.7 using PSL and non-pH-sensitive liposomes for comparison. We characterised the pH-dependent...

Cite
Yang K, Tang M, Chang HH, et al. Mannosylation of pH-sensitive liposomes promoted cytoplasmic delivery of protein to macrophages: green fluorescent protein (GFP) performed as an endosomal escape tracer. Pharm Dev Technol. 2021;26(9):1000-1009doi: 10.1080/10837450.2021.1969406.
Yang, K., Tang, M., Chang, H. H., Kanamala, M., Davidson, A. J., & Wu, Z. (2021). Mannosylation of pH-sensitive liposomes promoted cytoplasmic delivery of protein to macrophages: green fluorescent protein (GFP) performed as an endosomal escape tracer. Pharmaceutical development and technology, 26(9), 1000-1009. https://doi.org/10.1080/10837450.2021.1969406
Yang, Kaiyun, et al. "Mannosylation of pH-sensitive liposomes promoted cytoplasmic delivery of protein to macrophages: green fluorescent protein (GFP) performed as an endosomal escape tracer." Pharmaceutical development and technology vol. 26,9 (2021): 1000-1009. doi: https://doi.org/10.1080/10837450.2021.1969406
Yang K, Tang M, Chang HH, Kanamala M, Davidson AJ, Wu Z. Mannosylation of pH-sensitive liposomes promoted cytoplasmic delivery of protein to macrophages: green fluorescent protein (GFP) performed as an endosomal escape tracer. Pharm Dev Technol. 2021 Nov;26(9):1000-1009. doi: 10.1080/10837450.2021.1969406. Epub 2021 Aug 26. PMID: 34396913.
Copy Download .nbib Format: NLM
Trustworthy Clinical Practice Guidelines of Pharmacological Treatments for Hospitalized Patients With COVID-19-A Scarce Resource.

JAMA network open

Davidson KW, Alfano CM, Hill-Briggs F.
PMID: 34889950
JAMA Netw Open. 2021 Dec 01;4(12):e2138621. doi: 10.1001/jamanetworkopen.2021.38621.

No abstract available.

Cite
Davidson KW, Alfano CM, Hill-Briggs F. Trustworthy Clinical Practice Guidelines of Pharmacological Treatments for Hospitalized Patients With COVID-19-A Scarce Resource. JAMA Netw Open. 2021;4(12):e2138621doi: 10.1001/jamanetworkopen.2021.38621.
Davidson, K. W., Alfano, C. M., & Hill-Briggs, F. (2021). Trustworthy Clinical Practice Guidelines of Pharmacological Treatments for Hospitalized Patients With COVID-19-A Scarce Resource. JAMA network open, 4(12), e2138621. https://doi.org/10.1001/jamanetworkopen.2021.38621
Davidson, Karina W, et al. "Trustworthy Clinical Practice Guidelines of Pharmacological Treatments for Hospitalized Patients With COVID-19-A Scarce Resource." JAMA network open vol. 4,12 (2021): e2138621. doi: https://doi.org/10.1001/jamanetworkopen.2021.38621
Davidson KW, Alfano CM, Hill-Briggs F. Trustworthy Clinical Practice Guidelines of Pharmacological Treatments for Hospitalized Patients With COVID-19-A Scarce Resource. JAMA Netw Open. 2021 Dec 01;4(12):e2138621. doi: 10.1001/jamanetworkopen.2021.38621. PMID: 34889950.
Copy Download .nbib Format: NLM
ACC/AHA guidelines for the clinical application of echocardiography: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography.

Journal of the American College of Cardiology

Cheitlin MD, Alpert JS, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davidson TW, Davis JL, Douglas PS, Gillam LD, Lewis RP, Pearlman AS, Philbrick JT, Shah PM, Williams RG, Ritchie JL, Eagle KA, Gardner TJ, Garson A, Gibbons RJ, O'Rourke RA, Ryan TJ.
PMID: 9091535
J Am Coll Cardiol. 1997 Mar 15;29(4):862-79. doi: 10.1016/s0735-1097(96)90000-5.

No abstract available.

Cite
Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA guidelines for the clinical application of echocardiography: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography. J Am Coll Cardiol. 1997;29(4):862-79doi: 10.1016/s0735-1097(96)90000-5.
Cheitlin, M. D., Alpert, J. S., Armstrong, W. F., Aurigemma, G. P., Beller, G. A., Bierman, F. Z., Davidson, T. W., Davis, J. L., Douglas, P. S., Gillam, L. D., Lewis, R. P., Pearlman, A. S., Philbrick, J. T., Shah, P. M., Williams, R. G., Ritchie, J. L., Eagle, K. A., Gardner, T. J., Garson, A., Gibbons, R. J., O'Rourke, R. A., & Ryan, T. J. (1997). ACC/AHA guidelines for the clinical application of echocardiography: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography. Journal of the American College of Cardiology, 29(4), 862-79. https://doi.org/10.1016/s0735-1097(96)90000-5
Cheitlin, M D, et al. "ACC/AHA guidelines for the clinical application of echocardiography: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography." Journal of the American College of Cardiology vol. 29,4 (1997): 862-79. doi: https://doi.org/10.1016/s0735-1097(96)90000-5
Cheitlin MD, Alpert JS, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davidson TW, Davis JL, Douglas PS, Gillam LD, Lewis RP, Pearlman AS, Philbrick JT, Shah PM, Williams RG, Ritchie JL, Eagle KA, Gardner TJ, Garson A, Gibbons RJ, O'Rourke RA, Ryan TJ. ACC/AHA guidelines for the clinical application of echocardiography: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography. J Am Coll Cardiol. 1997 Mar 15;29(4):862-79. doi: 10.1016/s0735-1097(96)90000-5. PMID: 9091535.
Copy Download .nbib Format: NLM
Coding Errors in Study of Factors Associated With SARS-CoV-2 Antibodies in Health Care Personnel.

JAMA

Davidson KW.
PMID: 33289819
JAMA. 2020 Dec 08;324(22):2328. doi: 10.1001/jama.2020.20994.

No abstract available.

Cite
Davidson KW. Coding Errors in Study of Factors Associated With SARS-CoV-2 Antibodies in Health Care Personnel. JAMA. 2020;324(22):2328doi: 10.1001/jama.2020.20994.
Davidson, K. W. (2020). Coding Errors in Study of Factors Associated With SARS-CoV-2 Antibodies in Health Care Personnel. JAMA, 324(22), 2328. https://doi.org/10.1001/jama.2020.20994
Davidson, Karina W. "Coding Errors in Study of Factors Associated With SARS-CoV-2 Antibodies in Health Care Personnel." JAMA vol. 324,22 (2020): 2328. doi: https://doi.org/10.1001/jama.2020.20994
Davidson KW. Coding Errors in Study of Factors Associated With SARS-CoV-2 Antibodies in Health Care Personnel. JAMA. 2020 Dec 08;324(22):2328. doi: 10.1001/jama.2020.20994. PMID: 33289819.
Copy Download .nbib Format: NLM
PTPN21/Pez Is a Novel and Evolutionarily Conserved Key Regulator of Inflammation In Vivo.

Current biology : CB

Campbell JS, Davidson AJ, Todd H, Rodrigues FSLM, Elliot AM, Early JJ, Lyons DA, Feng Y, Wood W.
PMID: 33296680
Curr Biol. 2021 Feb 22;31(4):875-883.e5. doi: 10.1016/j.cub.2020.11.014. Epub 2020 Dec 08.

Drosophila provides a powerful model in which to study inflammation in vivo, and previous studies have revealed many of the key signaling events critical for recruitment of immune cells to tissue damage. In the fly, wounding stimulates the rapid...

Cite
Campbell JS, Davidson AJ, Todd H, et al. PTPN21/Pez Is a Novel and Evolutionarily Conserved Key Regulator of Inflammation In Vivo. Curr Biol. 2020;31(4):875-883.e5doi: 10.1016/j.cub.2020.11.014.
Campbell, J. S., Davidson, A. J., Todd, H., Rodrigues, F. S. L. M., Elliot, A. M., Early, J. J., Lyons, D. A., Feng, Y., & Wood, W. (2021). PTPN21/Pez Is a Novel and Evolutionarily Conserved Key Regulator of Inflammation In Vivo. Current biology : CB, 31(4), 875-883.e5. https://doi.org/10.1016/j.cub.2020.11.014
Campbell, Jennie S, et al. "PTPN21/Pez Is a Novel and Evolutionarily Conserved Key Regulator of Inflammation In Vivo." Current biology : CB vol. 31,4 (2021): 875-883.e5. doi: https://doi.org/10.1016/j.cub.2020.11.014
Campbell JS, Davidson AJ, Todd H, Rodrigues FSLM, Elliot AM, Early JJ, Lyons DA, Feng Y, Wood W. PTPN21/Pez Is a Novel and Evolutionarily Conserved Key Regulator of Inflammation In Vivo. Curr Biol. 2021 Feb 22;31(4):875-883.e5. doi: 10.1016/j.cub.2020.11.014. Epub 2020 Dec 08. PMID: 33296680; PMCID: PMC7902905.
Copy Download .nbib Format: NLM
Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group.

Journal of clinical lipidology

Wilson PWF, Jacobson TA, Martin SS, Jackson EJ, Le NA, Davidson MH, Vesper HW, Frikke-Schmidt R, Ballantyne CM, Remaley AT.
PMID: 34802986
J Clin Lipidol. 2021 Sep-Oct;15(5):629-648. doi: 10.1016/j.jacl.2021.09.046. Epub 2021 Sep 24.

Lipoprotein measurements are pivotal in the management of patients at risk for atherosclerotic coronary heart disease (CHD) with myocardial infarction and coronary death as the main outcomes, and for atherosclerotic cardiovascular disease (ASCVD), which includes CHD and stroke. Recent...

Cite
Wilson PWF, Jacobson TA, Martin SS, et al. Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. J Clin Lipidol. 2021;15(5):629-648doi: 10.1016/j.jacl.2021.09.046.
Wilson, P. W. F., Jacobson, T. A., Martin, S. S., Jackson, E. J., Le, N. A., Davidson, M. H., Vesper, H. W., Frikke-Schmidt, R., Ballantyne, C. M., & Remaley, A. T. (2021). Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. Journal of clinical lipidology, 15(5), 629-648. https://doi.org/10.1016/j.jacl.2021.09.046
Wilson, Peter W F, et al. "Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group." Journal of clinical lipidology vol. 15,5 (2021): 629-648. doi: https://doi.org/10.1016/j.jacl.2021.09.046
Wilson PWF, Jacobson TA, Martin SS, Jackson EJ, Le NA, Davidson MH, Vesper HW, Frikke-Schmidt R, Ballantyne CM, Remaley AT. Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. J Clin Lipidol. 2021 Sep-Oct;15(5):629-648. doi: 10.1016/j.jacl.2021.09.046. Epub 2021 Sep 24. PMID: 34802986.
Copy Download .nbib Format: NLM
Showing 529 to 539 of 539 entries